Pharmacotherapeutic strategies for hepatitis B and hepatitis C coinfection

References

• World Health Organization. Global hepatitis report 2017. [cited 15 September 2021]. Available from: https://apps.who.int/iris/handle/10665/255016
   Google Scholar
• Foreman KJ, Marquez N, Dolgert A, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories. Lancet. 2018 Nov 10;392(10159):2052–2090.
   PubMed Web of Science ®Google Scholar
• Caccamo G, Saffioti F, Raimondo G. Hepatitis B virus and hepatitis C virus dual infection. World J Gastroenterol. 2014 Oct 28;20(40):14559–14567.
   PubMed Web of Science ®Google Scholar
• Konstantinou D, Deutsch M. The spectrum of HBV/HCV coinfection: epidemiology, clinical characteristics, viralinteractions and management. Ann Gastroenterol. 2015 Apr-Jun;28(2):221–228.
   PubMed Web of Science ®Google Scholar
• Lacombe K, Rockstroh J. HIV and viral hepatitis coinfections: advances and challenges. Gut. 2012 May;61(Suppl 1):i47–58.
   PubMed Web of Science ®Google Scholar
• Donato F, Boffetta P, Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer. 1998 Jan 30;75(3):347–354.
   PubMed Web of Science ®Google Scholar
• Weltman MD, Brotodihardjo A, Crewe EB, et al. Coinfection with hepatitis B and C or B, C and delta viruses results in severe chronic liver disease and responds poorly to interferon-alpha treatment. J Viral Hepat. 1995;2(1):39–45.
   PubMed Web of Science ®Google Scholar
• Crockett SD, Keeffe EB. Natural history and treatment of hepatitis B virus and hepatitis C virus coinfection. Ann Clin Microbiol Antimicrob. 2005 Sep 13;4(1):13.
   PubMedGoogle Scholar
• Gaeta GB, Stornaiuolo G, Precone DF, et al. Epidemiological and clinical burden of chronic hepatitis B virus/hepatitis C virus infection. A multicenter Italian study. J Hepatol. 2003 Dec;39(6):1036–1041.
   PubMed Web of Science ®Google Scholar
• Semnani S, Roshandel G, Abdolahi N, et al. Hepatitis B/C virus co-infection in Iran: a seroepidemiological study. Turk J Gastroenterol. 2007 Mar;18(1):20–21.
   PubMed Web of Science ®Google Scholar
• Ohkawa K, Hayashi N, Yuki N, et al. Hepatitis C virus antibody and hepatitis C virus replication in chronic hepatitis B patients. J Hepatol. 1994 Oct;21(4):509–514.
   PubMed Web of Science ®Google Scholar
• Chan CY, Lee SD, Wu JC, et al. Superinfection with hepatitis C virus in patients with symptomatic chronic hepatitis B. Scand J Infect Dis. 1991;23(4):421–424.
   PubMed Web of Science ®Google Scholar
• Dai CY, Yu ML, Chuang WL, et al. Influence of hepatitis C virus on the profiles of patients with chronic hepatitis B virus infection. J Gastroenterol Hepatol. 2001 Jun;16(6):636–640.
   PubMed Web of Science ®Google Scholar
• Li W, Zhu Y, Hua Z. Exploration on the association between the pattern of HBV markers and infection of HCV among population. Zhonghua Liu Xing Bing Xue Za Zhi. 1994 Aug;15(4):212–214.
   PubMedGoogle Scholar
• Chen X, Xuan M, Wu D. Study of superinfection of HBV and HCV. Zhonghua Liu Xing Bing Xue Za Zhi. 1999 Jun;20(3):141–143.
   PubMedGoogle Scholar
• Fong TL, Di Bisceglie AM, Waggoner JG, et al. The significance of antibody to hepatitis C virus in patients with chronic hepatitis B. Hepatology. 1991 Jul;14(1):64–67.
   PubMed Web of Science ®Google Scholar
• Crespo J, Lozano JL, de La Cruz F, et al. Prevalence and significance of hepatitis C viremia in chronic active hepatitis B. Am J Gastroenterol. 1994 Aug;89(8):1147–1151.
   PubMed Web of Science ®Google Scholar
• Yan LB, Rao HY, Ma YJ, et al. Hepatitis B virus infection in Chinese patients with hepatitis C virus infection: prevalence, clinical characteristics, viral interactions and host genotypes: a nationwide cross-sectional study. BMJ Open. 2016 Oct 12;6(10):e012016.
   PubMed Web of Science ®Google Scholar
• Subramaniam S, Wong VW, Tse YK, et al. Impact of diabetes mellitus and hepatitis B virus coinfection on patients with chronic hepatitis C: a territory-wide cohort study. J Gastroenterol Hepatol. 2018 Apr;33(4):934–941.
   PubMed Web of Science ®Google Scholar
• Tyson GL, Kramer JR, Duan Z, et al. Prevalence and predictors of hepatitis B virus coinfection in a United States cohort of hepatitis C virus-infected patients. Hepatology. 2013 Aug;58(2):538–545.
   PubMed Web of Science ®Google Scholar
• Bini EJ, Perumalswami PV. Hepatitis B virus infection among American patients with chronic hepatitis C virus infection: prevalence, racial/ethnic differences, and viral interactions. Hepatology. 2010 Mar;51(3):759–766.
   PubMed Web of Science ®Google Scholar
• Tsatsralt-Od B, Takahashi M, Endo K, et al. Prevalence of hepatitis B, C, and delta virus infections among children in Mongolia: progress in childhood immunization. J Med Virol. 2007 Aug;79(8):1064–1074.
   PubMed Web of Science ®Google Scholar
• Tsatsralt-Od B, Takahashi M, Nishizawa T, et al. High prevalence of dual or triple infection of hepatitis B, C, and delta viruses among patients with chronic liver disease in Mongolia. J Med Virol. 2005 Dec;77(4):491–499.
   PubMed Web of Science ®Google Scholar
• Saravanan S, Velu V, Nandakumar S, et al. Hepatitis B virus and hepatitis C virus dual infection among patients with chronic liver disease. J Microbiol Immunol Infect. 2009 Apr;42(2):122–128.
   PubMedGoogle Scholar
• Chakravarti A, Verma V, Jain M, et al. Characteristics of dual infection of hepatitis B and C viruses among patients with chronic liver disease: a study from tertiary care hospital. Trop Gastroenterol. 2005 Oct-Dec;26(4):183–187.
   PubMedGoogle Scholar
• Murad EA, Babiker SM, Gasim GI, et al. Epidemiology of hepatitis B and hepatitis C virus infections in pregnant women in Sana’a, Yemen. BMC Pregnancy Childbirth. 2013 Jun 7;13(1):127.
   PubMedGoogle Scholar
• Nnakenyi ID, Uchechukwu C, Nto-Ezimah U. Prevalence of hepatitis B and C virus co-infection in HIV positive patients attending a health institution in southeast Nigeria. Afr Health Sci. 2020 Jun;20(2):579–586.
   PubMed Web of Science ®Google Scholar
• Reddy GA, Dakshinamurthy KV, Neelaprasad P, et al. Prevalence of HBV and HCV dual infection in patients on haemodialysis. Indian J Med Microbiol. 2005 Jan;23(1):41–43.
   PubMedGoogle Scholar
• Xess A, Kumar M, Minz S, et al. Prevalence of hepatitis B and hepatitis C virus coinfection in chronic liver disease. Indian J Pathol Microbiol. 2001 Jul;44(3):253–255.
   PubMedGoogle Scholar
• Mouzannar K, Liang TJ. Hepatitis B virus - recent therapeutic advances and challenges to cure. J Hepatol. 2020 Sep;73(3):694–695.
   PubMed Web of Science ®Google Scholar
• Raimondo G, Saitta C. Treatment of the hepatitis B virus and hepatitis C virus co-infection: still a challenge for the hepatologist. J Hepatol. 2008 Nov;49(5):677–679.
   PubMed Web of Science ®Google Scholar
• Sagnelli E, Coppola N, Messina V, et al. HBV superinfection in hepatitis C virus chronic carriers, viral interaction, and clinical course. Hepatology. 2002 Nov;36(5):1285–1291.
   PubMed Web of Science ®Google Scholar
• Chu CM, Yeh CT, Liaw YF. Low-level viremia and intracellular expression of hepatitis B surface antigen (HBsAg) in HBsAg carriers with concurrent hepatitis C virus infection. J Clin Microbiol. 1998 Jul;36(7):2084–2086.
   PubMed Web of Science ®Google Scholar
• Sheen IS, Liaw YF, Lin DY, et al. Role of hepatitis C and delta viruses in the termination of chronic hepatitis B surface antigen carrier state: a multivariate analysis in a longitudinal follow-up study. J Infect Dis. 1994 Aug;170(2):358–361.
   PubMed Web of Science ®Google Scholar
• Liaw YF, Lin SM, Sheen IS, et al. Acute hepatitis C virus superinfection followed by spontaneous HBeAg seroconversion and HBsAg elimination. Infection. 1991 Jul-Aug;19(4):250–251.
   PubMed Web of Science ®Google Scholar
• Liaw Y-F, Tsai S-L, Chang -J-J, et al. Displacement of hepatitis B virus by hepatitis C virus as the cause of continuing chronic hepatitis. Gastroenterology. 1994 Apr;106(4):1048–1053.
   PubMedGoogle Scholar
• Shih CM, Lo SJ, Miyamura T, et al. Suppression of hepatitis B virus expression and replication by hepatitis C virus core protein in HuH-7 cells. J Virol. 1993 Oct;67(10):5823–5832.
   PubMed Web of Science ®Google Scholar
• Schüttler CG, Fiedler N, Schmidt K, et al. Suppression of hepatitis B virus enhancer 1 and 2 by hepatitis C virus core protein. J Hepatol. 2002 Dec;37(6):855–862.
   PubMed Web of Science ®Google Scholar
• Chen SY, Kao CF, Chen CM, et al. Mechanisms for inhibition of hepatitis B virus gene expression and replication by hepatitis C virus core protein. J Biol Chem. 2003 Jan 3;278(1):591–607.
   PubMed Web of Science ®Google Scholar
• Pan Y, Wei W, Kang L, et al. NS5A protein of HCV enhances HBV replication and resistance to interferon response. Biochem Biophys Res Commun. 2007 Jul 20;359(1):70–75.
   PubMed Web of Science ®Google Scholar
• Guo H, Zhou T, Jiang D, et al. Regulation of hepatitis B virus replication by the phosphatidylinositol 3-kinase-akt signal transduction pathway. J Virol. 2007 Sep;81(18):10072–10080.
   PubMed Web of Science ®Google Scholar
• Bellecave P, Gouttenoire J, Gajer M, et al. Hepatitis B and C virus coinfection: a novel model system reveals the absence of direct viral interference. Hepatology. 2009 Jul;50(1):46–55.
   PubMed Web of Science ®Google Scholar
• Eyre NS, Phillips RJ, Bowden S, et al. Hepatitis B virus and hepatitis C virus interaction in Huh-7 cells. J Hepatol. 2009 Sep;51(3):446–457.
   PubMed Web of Science ®Google Scholar
• Yang D, Zuo C, Wang X, et al. Complete replication of hepatitis B virus and hepatitis C virus in a newly developed hepatoma cell line. Proc Natl Acad Sci U S A. 2014 Apr 1;111(13):E1264–73.
   PubMed Web of Science ®Google Scholar
• Pawlotsky JM. Virology of hepatitis B and C viruses and antiviral targets. J Hepatol. 2006;44(1 Suppl):S10–3.
   PubMedGoogle Scholar
• Mutz P, Metz P, Lempp FA, et al. HBV bypasses the innate immune response and does not protect HCV from antiviral activity of interferon. Gastroenterology. 2018 May;154(6):1791–1804.e22.
   PubMed Web of Science ®Google Scholar
• Ibarra R. Treatment of HBV-HCV coinfection. Ann Hepatol. 2006 Jan 01;5:S49–S52.
   PubMedGoogle Scholar
• Chu CJ, Lee SD. Hepatitis B virus/hepatitis C virus coinfection: epidemiology, clinical features, viral interactions and treatment. J Gastroenterol Hepatol. 2008 Apr;23(4):512–520.
   PubMed Web of Science ®Google Scholar
• Mavilia MG, Wu GY. HBV-HCV coinfection: viral interactions, management, and viral reactivation. J Clin Transl Hepatol. 2018 Sep 28;6(3):296–305.
   PubMed Web of Science ®Google Scholar
• Soriano V, Barreiro P, Martín-Carbonero L, et al. Treatment of chronic hepatitis B or C in HIV-infected patients with dual viral hepatitis. J Infect Dis. 2007 Apr 15;195(8):1181–1183.
   PubMed Web of Science ®Google Scholar
• Nguyen LH, Ko S, Wong SS, et al. Ethnic differences in viral dominance patterns in patients with hepatitis B virus and hepatitis C virus dual infection. Hepatology. 2011 Jun;53(6):1839–1845.
   PubMed Web of Science ®Google Scholar
• Wiegand SB, Jaroszewicz J, Potthoff A, et al. Dominance of hepatitis C virus (HCV) is associated with lower quantitative hepatitis B surface antigen and higher serum interferon-γ-induced protein 10 levels in HBV/HCV-coinfected patients. Clin Microbiol Infect. 2015 Jul;21(7):710.e1–9.
   Google Scholar
• Sagnelli E, Coppola N, Scolastico C, et al. Virologic and clinical expressions of reciprocal inhibitory effect of hepatitis B, C, and delta viruses in patients with chronic hepatitis. Hepatology. 2000 Nov;32(5):1106–1110.
   PubMed Web of Science ®Google Scholar
• Perz JF, Armstrong GL, Farrington LA, et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006 Oct;45(4):529–538.
   PubMed Web of Science ®Google Scholar
• Pol S, Haour G, Fontaine H, et al. The negative impact of HBV/HCV coinfection on cirrhosis and its consequences. Aliment Pharmacol Ther. 2017 Dec;46(11–12):1054–1060.
   PubMed Web of Science ®Google Scholar
• Tanaka H, Tsukuma H, Yamano H, et al. Prospective study on the risk of hepatocellular carcinoma among hepatitis C virus-positive blood donors focusing on demographic factors, alanine aminotransferase level at donation and interaction with hepatitis B virus. Int J Cancer. 2004 Dec 20;112(6):1075–1080.
   PubMed Web of Science ®Google Scholar
• Huang YT, Jen CL, Yang HI, et al. Lifetime risk and sex difference of hepatocellular carcinoma among patients with chronic hepatitis B and C. J Clin Oncol. 2011 Sep 20;29(27):3643–3650.
   PubMed Web of Science ®Google Scholar
• Zarski JP, Bohn B, Bastie A, et al. Characteristics of patients with dual infection by hepatitis B and C viruses. J Hepatol. 1998 Jan;28(1):27–33.
   PubMed Web of Science ®Google Scholar
• Kirk GD, Lesi OA, Mendy M, et al. The Gambia liver cancer study: infection with hepatitis B and C and the risk of hepatocellular carcinoma in West Africa. Hepatology. 2004 Jan;39(1):211–219.
   PubMed Web of Science ®Google Scholar
• Huang YT, Yang HI, Liu J, et al. Mediation analysis of hepatitis B and C in relation to hepatocellular carcinoma risk. Epidemiology. 2016 Jan;27(1):14–20.
   PubMed Web of Science ®Google Scholar
• Lin SH, Huang YT, Yang HI. On identification of agonistic interaction: hepatitis B and C interaction on hepatocellular carcinoma. Stat Med. 2019 Jun 15;38(13):2467–2476.
   PubMed Web of Science ®Google Scholar
• DA Drug Safety Communication: FDA warns about the risk of hepatitis B reactivating in some patients treated with direct-acting antivirals for hepatitis C: US Food and Drug Administration; 2016. [cited 1 September 1]. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm522932.htm
   Google Scholar
• Collins JM, Raphael KL, Terry C, et al. Hepatitis B virus reactivation during successful treatment of hepatitis C virus with sofosbuvir and simeprevir. Clin Infect Dis. 2015 Oct 15;61(8):1304–1306.
   PubMed Web of Science ®Google Scholar
• De Monte A, Courjon J, Anty R, et al. Direct-acting antiviral treatment in adults infected with hepatitis C virus: reactivation of hepatitis B virus coinfection as a further challenge. J Clin Virol. 2016 May;78:27–30.
   PubMed Web of Science ®Google Scholar
• Ende AR, Kim NH, Yeh MM, et al. Fulminant hepatitis B reactivation leading to liver transplantation in a patient with chronic hepatitis C treated with simeprevir and sofosbuvir: a case report. J Med Case Rep. 2015 Jul 28;9(1):164.
   PubMedGoogle Scholar
• Wang C, Ji D, Chen J, et al. Hepatitis due to reactivation of hepatitis B virus in endemic areas among patients with hepatitis C treated with direct-acting antiviral agents. Clin Gastroenterol Hepatol. 2017 Jan;15(1):132–136.
   PubMed Web of Science ®Google Scholar
• Mücke MM, Backus LI, Mücke VT, et al. Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2018 Mar;3(3):172–180.
   PubMed Web of Science ®Google Scholar
• El Kassas M, Shimakawa Y, Ali-Eldin Z, et al. Risk of hepatitis B virus reactivation with direct-acting antivirals against hepatitis C virus: a cohort study from Egypt and meta-analysis of published data. Liver Int. 2018 Dec;38(12):2159–2169.
   PubMed Web of Science ®Google Scholar
• Jiang XW, Ye JZ, Li YT, et al. Hepatitis B reactivation in patients receiving direct-acting antiviral therapy or interferon-based therapy for hepatitis C: a systematic review and meta-analysis. World J Gastroenterol. 2018 Jul 28;24(28):3181–3191.
   PubMed Web of Science ®Google Scholar
• Chen G, Wang C, Chen J, et al. Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: a systematic review and meta-analysis. Hepatology. 2017 Jul;66(1):13–26.
   PubMed Web of Science ®Google Scholar
• Poola S, Sanaka S, Sewell K, et al. Hepatitis B surface antibody titres and hepatitis B reactivation with direct-acting antiviral therapy for hepatitis C. J Viral Hepat. 2021 Feb;28(2):373–382.
   PubMed Web of Science ®Google Scholar
• Belperio PS, Shahoumian TA, Mole LA, et al. Evaluation of hepatitis B reactivation among 62,920 veterans treated with oral hepatitis C antivirals. Hepatology. 2017 Jul;66(1):27–36.
   PubMedGoogle Scholar
• Jaroszewicz J, Pawłowska M, Simon K, et al. Low risk of HBV reactivation in a large European cohort of HCV/HBV coinfected patients treated with DAA. Expert Rev Anti Infect Ther. 2020 Oct;18(10):1045–1054.
   PubMed Web of Science ®Google Scholar
• Tamori A, Abiru S, Enomoto H, et al. Low incidence of hepatitis B virus reactivation and subsequent hepatitis in patients with chronic hepatitis C receiving direct-acting antiviral therapy. J Viral Hepat. 2018 May;25(5):608–611.
   PubMed Web of Science ®Google Scholar
• Calvaruso V, Ferraro D, Licata A, et al. HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct-acting antivirals. J Viral Hepat. 2018 Jan;25(1):72–79.
   PubMed Web of Science ®Google Scholar
• Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018 Apr;67(4):1560–1599.
   PubMed Web of Science ®Google Scholar
• EASL. Clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017 Aug;67(2):370–398.
   PubMed Web of Science ®Google Scholar
• Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016 Jan;10(1):1–98.
   PubMed Web of Science ®Google Scholar
• Kanda T, Lau GKK, Wei L, et al. APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation. Hepatol Int. 2019 Nov;13(6):649–661.
   PubMed Web of Science ®Google Scholar
• Arribas JR, González-García JJ, Lorenzo A, et al. Single (B or C), dual (BC or BD) and triple (BCD) viral hepatitis in HIV-infected patients in Madrid, Spain. Aids. 2005 Sep 2;19(13):1361–1365.
   PubMed Web of Science ®Google Scholar
• Sollima S, Caramma I, Menzaghi B, et al. Chronic coinfection with hepatitis B and hepatitis C viruses in an Italian population of HIV-infected patients. J Acquir Immune Defic Syndr. 2007 Apr 15;44(5):606–607.
   PubMed Web of Science ®Google Scholar
• Filippini P, Coppola N, Pisapia R, et al. Virological and clinical aspects of HBV-HCV coinfection in HIV positive patients. J Med Virol. 2007 Nov;79(11):1679–1685.
   PubMed Web of Science ®Google Scholar
• Maida I, Ríos MJ, Pérez-Saleme L, et al. Profile of patients triply infected with HIV and the hepatitis B and C viruses in the HAART era. AIDS Res Hum Retroviruses. 2008 May;24(5):679–683.
   PubMed Web of Science ®Google Scholar
• Núñez M, Maida I, Babudieri S, et al. Hepatitis C viremia in HIV/HCV-coinfected patients: lower levels in presence of chronic hepatitis B. HIV Clin Trials. 2005 Mar-Apr;6(2):103–106.
   PubMed Web of Science ®Google Scholar
• Fernández-Montero JV, Vispo E, Barreiro P, et al. Hepatitis delta is a major determinant of liver decompensation events and death in HIV-infected patients. Clin Infect Dis. 2014 Jun;58(11):1549–1553.
   PubMed Web of Science ®Google Scholar
• Gaeta GB, Precone DF, Cozzi-Lepri A, et al. Multiple viral infections. J Hepatol. 2006;44(1):S108–13.
   PubMedGoogle Scholar
• Lacombe K, Boyd A, Desvarieux M, et al. Impact of chronic hepatitis C and/or D on liver fibrosis severity in patients co-infected with HIV and hepatitis B virus. Aids. 2007 Nov 30;21(18):2546–2549.
   PubMed Web of Science ®Google Scholar
• Ghany MG, Morgan TR. Hepatitis C guidance 2019 update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America recommendations for testing, managing, and treating hepatitis C virus infection. Hepatology. 2020 Feb;71(2):686–721.
   PubMed Web of Science ®Google Scholar
• EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol. 2018 Aug;69(2):461–511.
   PubMed Web of Science ®Google Scholar
• Omata M, Kanda T, Wei L, et al. APASL consensus statements and recommendation on treatment of hepatitis C. Hepatol Int. 2016 Sep;10(5):702–726.
   PubMed Web of Science ®Google Scholar
• Liu YC, Jeng WJ, Cheng YT, et al. Incidence and predictors for abnormal liver function during direct-acting antiviral agents in chronic hepatitis C patients. Medicine (Baltimore). 2020 Sep 11;99(37):e21898.
   PubMed Web of Science ®Google Scholar